The push to improve cash-flow forecasts continues as companies gain visibility and push out their time frames.
Abbott Laboratories plans to sell more than $10 billion of fixed-income securities this week, according to Fox News, as it prepares to spin off its pharmaceutical operations into a new company, AbbVie.
Abbott announced Friday that it was offering to buy back up to $7.7 billion in nine outstanding debt issues that mature between 2014 and 2040. It said that its subsidiary, AbbVie, will sell debt and use the proceeds to pay Abbott a dividend.
See the full story here.
There are countless unpredictable variables outside of traditional risks that pose challenges to treasurers. But...
Our step-by-step checklist and planning guide will help institutional investors feel comfortable moving into separately...
Expense fraud is a crime that affects organizations large and small. Find out how you...
S&P Capital IQ's RatingsDirect delivers the actionable market intelligence you need for efficient credit analysis...
This white paper outlines four imperatives that accounting and finance professionals should adopt in order...
This complimentary report, "Expense Management for a New Decade", teaches you how to leverage a...
Research has found that companies currently leveraging mobile travel and expense management applications/portals have an...
Treasury & Risk meets its readers' needs through an editorial blend of strategic insights and tactical solutions on the topics that matter most to today's financial executives. More than just a magazine, T&R is a multi-platform professional community-a nexus where finance leaders can exchange ideas, share problems and develop solutions together.
© 2013 Treasury & Risk. A Summit Business Media publication. All Rights Reserved.
